Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels

被引:2
作者
Lee, Soo-Young [1 ]
Yoo, Tae-Kyung [1 ]
Kim, Jisun [1 ]
Chung, Il Yong [1 ]
Ko, Beom Seok [1 ]
Kim, Hee Jeong [1 ]
Lee, Jong Won [1 ]
Son, Byung Ho [1 ]
Lee, Sae Byul [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Div Breast Surg,Dept Surg, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
关键词
Microinvasive breast cancer; HER2; Disease-free survival; Local recurrence; CARCINOMA IN-SITU; RADIATION; PROGNOSIS; HER2;
D O I
10.1007/s10549-023-06955-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe clinical behavior, prognosis, and management of microinvasive breast cancer (MiBC) is controversial. We aimed to clarify its significance across different subtypes and the role of human epidermal growth factor receptor 2 (HER2) expression in MiBC.MethodsWe analyzed 1530 patients with T1mi (tumor size <= 0.1 cm), node-negative breast cancer who underwent breast conserving surgery or total mastectomy between 2001 and 2020 at the Asan Medical Center (AMC).ResultsWhen divided into four subtypes, hormone receptor (HR)+/HER2-, HR+ /HER2+ , HR-/HER2+ , and HR-/HER2-, HR-/HER2+ had the highest prevalence rate of 38.5% in MiBC patients. In a median follow-up period of 74 months (0-271 months), 103 (6.7%) patients had recurrent tumor, and 95 (6.2%) had local recurrence. Disease-free survival (DFS) and local recurrence-free survival (LRFS) were worst in the HR-/HER2+ group. The five-year DFS for the HR-/HER2+ group was 92.2%, while it was 97.1% for the HR+/HER2- group (p = 0.024 The five-year LRFS for HER2- patients were better than that of HER2+ MiBC patients, which were 97.1 and 93.8%, respectively (p = 0.010). Univariate and multivariate Cox regression analyses showed that the HR-/HER2+ group had relatively higher risk of recurrence compared to the HR+/HER2- group (hazard ratio [HR] = 2.332, 95% confidence interval [CI] 1.412-3.852, p = 0.001 unadjusted; HR = 3.346, 95% CI 1.408-7.953, p = 0.006 adjusted).ConclusionHER2 overexpression was significantly associated with adverse clinicopathologic parameters and increased local recurrence risk in MiBC. Therefore, more understanding of the clinical behavior of HER2 in MiBC will enable tailoring of adjuvant therapy for these patients.
引用
收藏
页码:47 / 61
页数:15
相关论文
共 23 条
[1]   The clinical significance of HER2 expression in DCIS [J].
Akrida, Ioanna ;
Mulita, Francesk .
MEDICAL ONCOLOGY, 2022, 40 (01)
[2]  
Cho SY, 2021, J BREAST CANCER, V24, P1
[3]   Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial [J].
Cobleigh, Melody A. ;
Anderson, Stewart J. ;
Siziopikou, Kalliopi P. ;
Arthur, Douglas W. ;
Rabinovitch, Rachel ;
Julian, Thomas B. ;
Parda, David S. ;
Seaward, Samantha A. ;
Carter, Dennis L. ;
Lyons, Janice A. ;
Dillmon, Melissa S. ;
Magrinat, Gustav C. ;
Kavadi, Vivek S. ;
Zibelli, Allison M. ;
Tiriveedhi, Lavanya ;
Hill, Matthew L. ;
Melnik, Marianne K. ;
Beriwal, Sushil ;
Mamounas, Eleftherios P. ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) :2367-+
[4]   Microinvasive breast carcinoma: An analysis from ten Senonetwork Italia breast centres [J].
Costarelli, Leopoldo ;
Cianchetti, Ettore ;
Corsi, Fabio ;
Friedman, Daniele ;
Ghilli, Matteo ;
Lacaria, MariaTeresa ;
Menghini, Lorenzo ;
Murgo, Roberto ;
Pond, Antonio ;
Rinaldi, Stefano ;
del Turco, Marco Rosselli ;
Taffurelli, Mario ;
Tinterri, Corrado ;
Tomatis, Mariano ;
Fortunato, Lucio .
EJSO, 2019, 45 (02) :147-152
[5]   Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion [J].
Fang, Yan ;
Wu, Jiayi ;
Wang, Wei ;
Fei, Xiaochun ;
Zong, Yu ;
Chen, Xiaosong ;
Huang, Ou ;
He, Jianrong ;
Chen, Weiguo ;
Li, Yafen ;
Shen, Kunwei ;
Zhu, Li .
ONCOTARGET, 2016, 7 (39) :64182-64190
[6]   Breast Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual [J].
Giuliano, Armando E. ;
Connolly, James L. ;
Edge, Stephen B. ;
Mittendorf, Elizabeth A. ;
Rugo, Hope S. ;
Solin, Lawrence J. ;
Weaver, Donald L. ;
Winchester, David J. ;
Hortobagyi, Gabriel N. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (04) :291-303
[7]   Breast Cancer, Version 3.2022 [J].
Gradishar, William J. ;
Moran, Meena S. ;
Abraham, Jame ;
Aft, Rebecca ;
Agnese, Doreen ;
Allison, Kimberly H. ;
Anderson, Bethany ;
Burstein, Harold J. ;
Chew, Helen ;
Dang, Chau ;
Elias, Anthony D. ;
Giordano, Sharon H. ;
Goetz, Matthew P. ;
Goldstein, Lori J. ;
Hurvitz, Sara A. ;
Isakoff, Steven J. ;
Jankowitz, Rachel C. ;
Javid, Sara H. ;
Krishnamurthy, Jairam ;
Leitch, Marilyn ;
Lyons, Janice ;
Mortimer, Joanne ;
Patel, Sameer A. ;
Pierce, Lori J. ;
Rosenberger, Laura H. ;
Rugo, Hope S. ;
Sitapati, Amy ;
Smith, Karen Lisa ;
Smith, Mary Lou ;
Soliman, Hatem ;
Stringer-Reasor, Erica M. ;
Telli, Melinda L. ;
Ward, John H. ;
Wisinski, Kari B. ;
Young, Jessica S. ;
Burns, Jennifer ;
Kumar, Rashmi .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (06) :691-722
[8]   Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study [J].
Hennigs, Andre ;
Riedel, Fabian ;
Gondos, Adam ;
Sinn, Peter ;
Schirmacher, Peter ;
Marme, Frederik ;
Jaeger, Dirk ;
Kauczor, Hans-Ulrich ;
Stieber, Anne ;
Lindel, Katja ;
Debus, Juergen ;
Golatta, Michael ;
Schuetz, Florian ;
Sohn, Christof ;
Heil, Joerg ;
Schneeweiss, Andreas .
BMC CANCER, 2016, 16
[9]  
Kim M, 2018, J BREAST CANCER, V21, P197
[10]   Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion [J].
Li, Chunyan ;
Yang, Yilan ;
Wang, Jiangfeng ;
Jin, Kairui ;
Yang, Zhaozhi ;
Yu, Xiaoli ;
Guo, Xiaomao ;
Chen, Xingxing .
CANCER MEDICINE, 2021, 10 (20) :7203-7212